Tivozanib
CAS No. 475108-18-0
Tivozanib ( AV-951;AV951;AV 951 )
产品货号. M14578 CAS No. 475108-18-0
A highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥275 | 有现货 |
|
5MG | ¥446 | 有现货 |
|
10MG | ¥616 | 有现货 |
|
25MG | ¥1175 | 有现货 |
|
50MG | ¥2041 | 有现货 |
|
100MG | ¥3645 | 有现货 |
|
200MG | ¥5370 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Tivozanib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述A highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3.
-
产品描述A highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3; also inhibits EphB2, PDGFR-α, PDGFR-β, c-Kit, and Tie2 (IC50=20-80 nM); inhibits VEGF-induced VEGFR-2 phosphorylation in endothelial cells (IC50=0.16 nM); p.o. active.Kidney Cancer Approved
-
同义词AV-951;AV951;AV 951
-
通路Angiogenesis
-
靶点VEGFR
-
受体EphB2;PDGFRα;VEGFR1;VEGFR2;VEGFR3
-
研究领域Cancer
-
适应症Kidney Cancer
化学信息
-
CAS Number475108-18-0
-
分子量454.86
-
分子式C22H19ClN4O5
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C(NC1=NOC(C)=C1)NC2=CC=C(OC3=CC=NC4=CC(OC)=C(OC)C=C34)C=C2Cl
-
化学全称Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Nakamura K, et al. Cancer Res. 2006 Sep 15;66(18):9134-42.
2. Eskens FA, et al. Clin Cancer Res. 2011 Nov 15;17(22):7156-63.
3. Momeny M, et al. Sci Rep. 2017 Apr 6;7:45954.
2. Eskens FA, et al. Clin Cancer Res. 2011 Nov 15;17(22):7156-63.
3. Momeny M, et al. Sci Rep. 2017 Apr 6;7:45954.
产品手册
关联产品
-
SU5208
SU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
-
Cabozantinib hydroch...
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
-
Pazopanib
A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.